Brian Leuthner
Founder bei Alivio Therapeutics, Inc.
Vermögen: - $ am 31.03.2024
Profil
Brian A.
Leuthner is the founder.
He founded Edge Therapeutics, Inc. in 2009 and held the title of President, Chief Executive Officer & Director.
Mr. Leuthner is also the founder of Alivio Therapeutics, Inc. Mr. Leuthner's former job(s) include being the Chief Executive Officer of Fontus Pharmaceuticals, Inc. from 2007 to 2008, Director-Market Development at ESP Pharma, Inc. from 2003 to 2005, and Senior Head-Marketing at The Medicines Co. from 2005 to 2007.
He also briefly served as the Chief Executive & Operating Officer at OncoSec Medical, Inc. in 2021.
Additionally, Mr. Leuthner held positions at Ortho Biotech Products LP and PDS Biotechnology Corp., with the title of Principal and Chief Executive Officer, respectively.
Mr. Leuthner's education history includes undergraduate studies and an MBA from The University of North Carolina at Chapel Hill.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 21.03.2023 | 1 564 ( 0,03% ) | - $ | 31.03.2024 |
Aktive Positionen von Brian Leuthner
| Unternehmen | Position | Beginn |
|---|---|---|
Alivio Therapeutics, Inc.
 Alivio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Alivio Therapeutics, Inc. develops therapies to treat inflammatory disorders through targeted disease immunomodulation. The company was founded by Robert S. Langer, Jeffrey Karp, John LaMattima, Brian Leuthner, Bennett Shapiro, Eric Elenko, Joep Muijrers, and Stephen Muniz and is headquartered in Boston, MA. | Founder | - |
Ehemalige bekannte Positionen von Brian Leuthner
| Unternehmen | Position | Ende |
|---|---|---|
| ONCOSEC MEDICAL INCORPORATED | Chief Executive Officer | 13.08.2021 |
| Fontus Pharmaceuticals, Inc. | Chief Executive Officer | 01.01.2008 |
| THE MEDICINES COMPANY | Sales & Marketing | 01.01.2007 |
ESP Pharma, Inc.
 ESP Pharma, Inc. Pharmaceuticals: MajorHealth Technology ESP Pharma, Inc. produces pharmaceutical products. The company used to produce drug for acute-care hospital use and these drugs include therapeutics for high blood pressure and angina; one product, IV Busulfex, is used to prepare myelogenous for leukemia patients for bone marrow transplants. The company formulates its products to be delivered intravenously or by injection when oral administration is impossible. The company was founded in April, 2002 and was headquartered in Edison, NJ | Corporate Officer/Principal | 01.01.2005 |
| PDS BIOTECHNOLOGY CORPORATION | Chief Executive Officer | - |
Ausbildung von Brian Leuthner
| The University of North Carolina at Chapel Hill | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ONCOSEC MEDICAL INCORPORATED | Health Services |
| PDS BIOTECHNOLOGY CORPORATION | Health Technology |
| Private Unternehmen | 6 |
|---|---|
The Medicines Co.
 The Medicines Co. Pharmaceuticals: MajorHealth Technology The Medicines Co. is a biopharmaceutical company, which focuses on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on acute and intensive care hospitals worldwide. The firm markets its brands Angiomax, Cleviprex, injectable emulsion, Ionsys, Kengreal, Minocin for injection, and Orbactiv. The company was founded by Clive A. Meanwell, Helmut Giersiefen, John W. Villiger and T. Scott Johnson on July 31, 1996 and is headquartered in Parsippany, NJ. | Health Technology |
ESP Pharma, Inc.
ESP Pharma, Inc. Pharmaceuticals: MajorHealth Technology ESP Pharma, Inc. produces pharmaceutical products. The company used to produce drug for acute-care hospital use and these drugs include therapeutics for high blood pressure and angina; one product, IV Busulfex, is used to prepare myelogenous for leukemia patients for bone marrow transplants. The company formulates its products to be delivered intravenously or by injection when oral administration is impossible. The company was founded in April, 2002 and was headquartered in Edison, NJ | Health Technology |
Edge Therapeutics, Inc.
 Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | Health Technology |
Ortho Biotech Products LP
 Ortho Biotech Products LP Pharmaceuticals: MajorHealth Technology Ortho Biotech Products LP provides innovative products and services which are designed to enhance the lives of individuals with serious chronic illnesses. The company's products include PROCRIT, DOXIL and LEUSTATIN. Ortho Biotech Products was founded in 1990 and is headquartered in Bridgewater, NJ | Health Technology |
| Fontus Pharmaceuticals, Inc. | |
Alivio Therapeutics, Inc.
Alivio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Alivio Therapeutics, Inc. develops therapies to treat inflammatory disorders through targeted disease immunomodulation. The company was founded by Robert S. Langer, Jeffrey Karp, John LaMattima, Brian Leuthner, Bennett Shapiro, Eric Elenko, Joep Muijrers, and Stephen Muniz and is headquartered in Boston, MA. | Health Technology |
